5 Most Undervalued American Stocks to Invest In

In this article, we will list the 5 Most Undervalued American Stocks to Invest In. Please visit 10 Most Undervalued American Stocks to Invest In if you would like to see the extended list and the methodology behind it.

5. HCA Healthcare, Inc. (NYSE:HCA)

On June 29, 2026, HCA Healthcare, Inc. (NYSE:HCA) announced new research published in The New England Journal of Medicine showing promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study evaluated exa-cel, a CRISPR-based cell therapy currently approved by the U.S. Food and Drug Administration for eligible patients ages 12 and older with sickle cell disease and transfusion-dependent beta thalassemia. Among participants followed long enough to evaluate the primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, while all eight children with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months.

On June 22, TD Cowen analyst Ryan Langston lowered the firm’s price target on HCA Healthcare to $431 from $500 and kept a Buy rating. Langston reduced TD Cowen’s 2026 and 2027 growth assumptions after its May hospital survey showed flat year-over-year revenue. Survey commentary pointed to weaker surgical volumes that were partially offset by growth in medical volumes.

In an 8-K filing, HCA Healthcare said Dr. Michael Cuffe and the company agreed on June 15 that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026. Dr. Cuffe will then continue in a transitional role with the company until February 2027 and will be eligible to receive benefits under HCA Healthcare’s executive severance policy and applicable incentive plans.

HCA Healthcare, Inc. (NYSE:HCA) provides health care services in the United States.